Intec Pharma Ltd
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jeffrey Meckler
- Full Time Employees
- 36
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 12 Hartom Street, Har Hotzvim Jerusalem Israel 9777512
- IPO Date
- Jul 30, 2015
- CIK
- 0001638381
- Website
- intecpharma.com
- Similar Companies
- Business
- Intec Pharma Ltd is a clinical-stage biopharmaceutical company that develops drugs based on its proprietary Accordion Pill platform technology, an oral drug delivery system designed to improve the efficacy and safety of existing drugs and those under development through efficient gastric retention and specific release mechanisms. The company's core products include Accordion Pill Carbidopa/Levodopa (AP-CD/LD) for treating symptoms of advanced Parkinson's disease, following completion of a Phase II clinical trial and agreement with the U.S. FDA on a Phase III development program; Accordion Pill platform formulations for cannabinoids such as cannabidiol (CBD) and tetrahydrocannabinol (THC) targeting indications like low back neuropathic pain and fibromyalgia; and exploratory applications for other proprietary compounds via partnerships. Founded in 2000 and headquartered in Jerusalem, Israel, Intec Pharma operates primarily in the biopharmaceutical sector with a focus on neurology and pain management, conducting research, development, and clinical trials globally. In recent major changes, Intec Pharma completed a reverse merger with Decoy Biosystems in August 2021, under which it became a wholly owned subsidiary of the combined entity, renamed Indaptus Therapeutics, Inc. (NASDAQ: INDP), resulting in delisting of its ordinary shares from Nasdaq and a shift away from its Accordion Pill business operations as a standalone public entity. The company executed a 1-for-4 reverse share split in July 2021 ahead of the merger and domestication to Delaware to meet listing requirements, while raising $30 million in private placement funding for working capital. Earlier collaborations included a 2018 feasibility and option agreement with Novartis Pharma and manufacturing partnership with LTS Lohmann Therapie-Systeme AG for AP-CD/LD production in Germany, though no recent 2024-2025 partnerships, funding rounds, or product launches are reported amid its subsidiary status.
Intec Announces Expected Closing Date of Decoy Merger
NTEC Stock: 10 Things to Know About Red-Hot Intec Pharma
3 Biotech Penny Stocks To Watch On Robinhood IPO Day
Hot Penny Stocks to Buy Now? 4 You Need to Know About
Best Penny Stocks To Buy Before Marijuana Legalization? 4 To Watch Now
Top 10 Biotech Penny Stocks to Watch in July 2021
Best Penny Stocks To Buy Now? 7 To Watch This Week
The Week Where New York Legalizes Recreational Marijuana
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Intec Pharma Ltd. - NTEC
SHAREHOLDER ALERT: WeissLaw LLP Investigates Intec Pharma Ltd.
Last Week's 7 Biggest Cannabis Moves
INTEC PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Intec Pharma Ltd. - NTEC
Intec Pharma Announces Filing of 2020 Annual Report on Form 10-K
NTEC Stock Price Increases Over 80% Pre-Market: Why It Happened
Intec Pharma and Decoy Biosystems Announce Merger Agreement
Intec Pharma (NTEC) Stock Price Jumped Over 100%: Why It Happened
Intec Pharma News: Why NTEC Stock Is on Fire Today
9 Cannabis Stocks Making Moves During an Explosive U.S. Election Week
Virios Therapeutics Seeks IPO For Fibromyalgia Pain Treatment
Intec Pharma (NTEC) Receives a Hold from H.C. Wainwright